



N:PA:AMPATM1404

#32/B
MB
11/25/97

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Kohn, et al.
Serial No. : 08/225,478
Filed : April 8, 1994
For : Gene Therapy by Administration of Genetically Engineered CD34+ Cells Obtained from Cord Blood
Group : 1819
Examiner : Stanton

Assistant Commissioner of Patents
Washington, D.C. 20231

RECEIVED
NOV 2 1997
CLASS 1819

AMENDMENT

SIR:

In response to the Office Action dated May 28, 1997, kindly amend the above-identified application as follows:

IN THE CLAIMS:

1. (Twice amended) A method of [providing] expressing a therapeutic [effect] agent in a human [patient], comprising:

8' administering autologous CD34+ cells obtained from cord blood to said [patient] human, said autologous CD34+ cells having been genetically engineered to include at least one nucleic acid sequence encoding a therapeutic agent[, said autologous CD34+ cells being administered in an amount effective to provide said patient with an effective amount of said therapeutic agent by expression of said nucleic acid sequence in said patient].